Panitumumab plus mFOLFOX6 therapy for colorectal cancer patients of RAS wild with potential resectable metastases in relation to early tumor shrinkage
Not Applicable
Recruiting
- Conditions
- colorectal cancer with potential resectable metastases
- Registration Number
- JPRN-UMIN000012832
- Lead Sponsor
- Chubu Clinical Oncology Group(CCOG)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
(1)Pleural effision or ascites or pericardial effusion to be discharged (2)Multiple malignacies to be treated (3)bleeding tendency(PT-INR ;1.5) (4)Ileus,uncontrollable peptic ulcer disease (5)Serious complications (DM, infection, diarrhea) (6)Serious heart disease (7)Previous history of severe drug-induced allergy (8)Severe neuropathy (9)With interstitial lung disease or pulmonary fibrosis (10)Pregnant (11)Disqualified by attending doctor
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Early tumor shrinkage(at the point of 8 weeks)
- Secondary Outcome Measures
Name Time Method